Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) Completed Phase 2 Trials for Methopterin (DB16620)

Also known as: Myelodysplastic Syndrome With Excess Blasts-2

IndicationStatusPhase
DBCOND0092771 (Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01858740Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in ChildrenTreatment